Australia Offers Hope For Drug Resistant Epilepsy Patients

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

More than 150,000 Australians and 50 million people across the world are affected by epilepsy, with almost one-third finding it challenging to control the condition with the anti-seizure medications that are currently in use. The patients with such drug-resistant epilepsy happen to have high rates of disability as well as mental health and thinking challenges, besides having worrisome injury and death rates as well.

It is now the first time that a new drug has been explored, which happens to be potentially the first curative drug for epilepsy in patients who have shown resistance to the current anti-seizure medications.

All the currently available medications that are used to treat people with epilepsy are symptomatic, reducing seizure frequency in less than 70% of the cases, but they have no sustained effect when it comes to subsiding or curing epilepsy or the conditions that are associated with it.

In research that was led by Professor Terry O’Brien and Dr. Pablo Casillas-Espinosa from the Neuroscience division of Monash University, the outcomes reported that sodium selenate can go on to become the first medical disease-modifying treatment when it comes to epilepsy.

Due to the strength of such findings and the promise they hold, the researchers have been awarded a $3 million Medical Research Future Fund grant to begin the clinical trial of sodium selenate as a treatment that happens to be curative in patients who have time and again shown epilepsy that is drug-resistant.

It is important to note that, overall, 124 patients will be enrolled across a minimum of nine sites in Australia over a period of two and a half years.

As per professor O’Brien, epilepsy happens to be one of the most serious but common brain disabling disorders, which is costly for both the individuals as well as their families and even to the national health budget, with an estimated annual economic cost across Australia of $12.3 billion.

Latest stories

Related stories

Singapore Seeking Pharmaceutical Tariff Concessions from US

The deputy prime minister and trade minister of Singapore,...

Merck to Acquire Verona for $10B, COPD Drug in Focus

Merck has pulled off another acquisition that happens to...

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back